Definium Therapeutics, Inc. is trading 5.2% down at $21.82 as the stock extends a multi-day pullback amid broader market weakness and higher-for-longer interest rate concerns.
- Shares are sliding alongside other growth and high-beta therapeutics names as investors react to macro volatility and a risk-off sentiment across major indices.
- With major indices down more than 1% and no fresh company-specific developments, the move appears primarily driven by sector-wide pressure rather than fundamental news.